Uveal melanoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{Fs}}, {{Simrat}} | {{CMG}}{{AE}}{{Fs}}, {{Simrat}} | ||
==Overview== | ==Overview== | ||
Pharmacologic medical therapy is recommended among [[Patient|patients]] with [[Metastasis|metastatic]] [[disease]] and include [[chemotherapy]], [[immunotherapy]], and [[targeted therapy]]. | |||
==Medical Therapy== | ==Medical Therapy== | ||
Pharmacologic medical [[therapy]] is recommended among [[Patient|patients]] with [[Metastasis|metastatic]] disease:<ref name="pmid29497459">{{cite journal |vauthors=Yang J, Manson DK, Marr BP, Carvajal RD |title=Treatment of uveal melanoma: where are we now? |journal=Ther Adv Med Oncol |volume=10 |issue= |pages=1758834018757175 |date=2018 |pmid=29497459 |pmc=5824910 |doi=10.1177/1758834018757175 |url=}}</ref> | |||
*[[Chemotherapy]] | |||
**[[Dacarbazine]] | |||
**[[Temozolomide]] | |||
**[[Cisplatin]] | |||
**[[Treosulfan]] | |||
**[[Fotemustine]] | |||
*[[Immunotherapy]] | |||
** Checkpoint blockade | |||
***[[Pembrolizumab]] | |||
***[[Ipilimumab]] + [[nivolumab]] | |||
***[[Ipilimumab]] + [[nivolumab]] | |||
***[[Ipilimumab]] + radioembolization | |||
***[[Ipilimumab]] + [[nivolumab]] +radioembolization | |||
** TILs (tumor-infiltrating lymphocytes) | |||
**[[T cell]] redirection | |||
**[[Antibody]]–[[drug]] conjugate | |||
*** Glembatumumab vedotin | |||
*[[Targeted therapy]] | |||
**[[Protein kinase C|PKC]] ([[protein kinase C]])/ MEK | |||
*** AEB071 + BYL719 | |||
*** Intermittent selumetinib | |||
*** Selumetinib +/– [[paclitaxel]] | |||
***[[Binimetinib]] + AEB071 | |||
** Multi-kinase inhibition | |||
***[[Sorafenib]] (STREAM) | |||
***[[Cabozantinib]] versus [[temozolomide]]/ [[dacarbazine]] | |||
** Epigenetic therapy | |||
***[[Histone deacetylase 2|HDAC]] ([[histone deacetylase]]) inhibition | |||
****[[Vorinostat]] | |||
****[[Pembrolizumab]] + entinostat (PEMDAC) | |||
*** BET (bromodomain and extra-terminal motif) inhibition | |||
** Liver-directed therapy | |||
*** IHP (isolated [[hepatic]] perfusion) | |||
*** PHP ( <br /> | |||
== References == | == References == | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 03:24, 16 August 2019
|
Uveal melanoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Uveal melanoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Uveal melanoma medical therapy |
|
Risk calculators and risk factors for Uveal melanoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Simrat Sarai, M.D. [2]
Overview
Pharmacologic medical therapy is recommended among patients with metastatic disease and include chemotherapy, immunotherapy, and targeted therapy.
Medical Therapy
Pharmacologic medical therapy is recommended among patients with metastatic disease:[1]
- Chemotherapy
- Immunotherapy
- Checkpoint blockade
- Pembrolizumab
- Ipilimumab + nivolumab
- Ipilimumab + nivolumab
- Ipilimumab + radioembolization
- Ipilimumab + nivolumab +radioembolization
- TILs (tumor-infiltrating lymphocytes)
- T cell redirection
- Antibody–drug conjugate
- Glembatumumab vedotin
- Checkpoint blockade
- Targeted therapy
- PKC (protein kinase C)/ MEK
- AEB071 + BYL719
- Intermittent selumetinib
- Selumetinib +/– paclitaxel
- Binimetinib + AEB071
- Multi-kinase inhibition
- Sorafenib (STREAM)
- Cabozantinib versus temozolomide/ dacarbazine
- Epigenetic therapy
- HDAC (histone deacetylase) inhibition
- Vorinostat
- Pembrolizumab + entinostat (PEMDAC)
- BET (bromodomain and extra-terminal motif) inhibition
- HDAC (histone deacetylase) inhibition
- Liver-directed therapy
- IHP (isolated hepatic perfusion)
- PHP (
- PKC (protein kinase C)/ MEK
References
- ↑ Yang J, Manson DK, Marr BP, Carvajal RD (2018). "Treatment of uveal melanoma: where are we now?". Ther Adv Med Oncol. 10: 1758834018757175. doi:10.1177/1758834018757175. PMC 5824910. PMID 29497459.